Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531568 | 1.00 | TSHR (0.52) | TSHRABCC4MAPTALDH1A1LMNA | |
| SCHEMBL8999819 | 1.00 | TSHR (0.52) | TSHRABCC4MAPTALDH1A1LMNA | |
| SCHEMBL129386 | 1.00 | — | — | |
| SCHEMBL2836775 | 1.00 | TSHR (0.52) | TSHRABCC4MAPTALDH1A1LMNA | |
| SCHEMBL41157 | 1.00 | TSHR (0.52) | TSHRABCC4MAPTALDH1A1LMNA | |
| SCHEMBL129761 | 1.00 | — | — | |
| SCHEMBL128643 | 1.00 | TSHR (0.52) | TSHRABCC4MAPTALDH1A1LMNA | |
| SCHEMBL129678 | 1.00 | TSHR (0.52) | TSHRABCC4MAPTALDH1A1LMNA | |
| SCHEMBL2834305 | 1.00 | TSHR (0.52) | TSHRABCC4MAPTALDH1A1LMNA | |
| SCHEMBL10718401 | 1.00 | TSHR (0.52) | TSHRABCC4MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775846-A | Bionic raw lacquer prepared from protocatechuic acid and preparation method thereof | 西北农林科技大学 | 2025-04-08 | — | — | CN | claimed |
| CN-114105517-B | Polycarboxylic acid high-performance water reducing agent | 福州创先工程材料有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-114105517-A | Polycarboxylic acid high-performance water reducing agent | 福州创先工程材料有限公司 | 2022-03-01 | — | — | CN | claimed |
| EP-3129347-A1 | REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES | California Institute of Technology (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157736-A1 | REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-10-15 | — | — | WO | claimed |
| US-20150284313-A1 | REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-08 | — | — | US | claimed |
| EP-1765894-B1 | NOVEL TEMPERATURE AND PH SENSITIVE COPOLYMERS | AGENCY SCIENCE TECH & RES (SG) | 2012-03-28 | — | — | EP | claimed |
| US-12595495-B2 | Methods of producing omega-hydroxylated fatty acid derivatives | GENOMATICA, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260035391-A1 | SILANE COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2026-02-05 | — | — | US | disclosed |
| EP-4678645-A1 | SILANE COMPOUND | Daikin Industries, Ltd. (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-20250361250-A1 | FLUORINE-CONTAINING SILANE COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| US-20250361405-A1 | COMPOSITION BASED ON A POLYMERIZABLE COMPONENT AND A THIXOTROPIC ADDITIVE | ARKEMA FRANCE (FR) | 2025-11-27 | — | — | US | disclosed |
| CN-119775846-A | Bionic raw lacquer prepared from protocatechuic acid and preparation method thereof | 西北农林科技大学 | 2025-04-08 | — | — | CN | disclosed |
| EP-0486011-A2 | Pharmaceutical composition against Pneumocystis carinii | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
| US-4960906-A | Process for the preparation of lactones from higher alkenols | SHELL OIL COMPANY (US) | 1990-10-02 | — | — | US | disclosed |
| EP-0341773-A1 | Process for the preparation of lactones | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-11-15 | — | — | EP | disclosed |
| US-4059488-A | CULTIVATION OF CANDIDA LIPOLYTICA | BIO RESEARCH CENTER, CO., LTD. (JA) | 1977-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595495-B2 | Methods of producing omega-hydroxylated fatty acid derivatives | CYP4F11, CYP2F1, CYP4Z1 | TSHR 1330/4885ABCC4 3203/4885MAPT 3723/4885 |
| US-20260035391-A1 | SILANE COMPOUND | OXER1, CBR1, MSR1 | TSHR 1167/4885ABCC4 3555/4885MAPT 3787/4885 |
| US-20250361250-A1 | FLUORINE-CONTAINING SILANE COMPOUND | FLI1, AFF1, RFT1 | TSHR 2035/4885ABCC4 4730/4885MAPT 4711/4885 |
| US-20150284313-A1 | REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES | DDC, LTC4S, CYCS | TSHR 4169/4885ABCC4 1599/4885MAPT 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.